Cellectar Biosciences (CLRB)
(Real Time Quote from BATS)
$2.92 USD
+0.40 (15.87%)
Updated Jul 22, 2024 11:52 AM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
CLRB 2.92 +0.40(15.87%)
Will CLRB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLRB
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
CLRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLRB
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million
Cellectar Biosciences Bolsters Capital with Warrant Exercise Strategy
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape
Cellectar Biosciences Shareholders Back Leadership and Incentives
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides